Wellington Management Group LLP Has $31.59 Million Stock Holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

Wellington Management Group LLP increased its position in shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,190,811 shares of the company's stock after acquiring an additional 148,088 shares during the period. Wellington Management Group LLP owned about 4.76% of CARGO Therapeutics worth $31,591,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of CRGX. Tower Research Capital LLC TRC raised its holdings in shares of CARGO Therapeutics by 565.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company's stock worth $84,000 after acquiring an additional 4,929 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in CARGO Therapeutics during the fourth quarter valued at about $141,000. Invesco Ltd. bought a new position in CARGO Therapeutics during the fourth quarter valued at about $165,000. ProShare Advisors LLC bought a new position in shares of CARGO Therapeutics in the fourth quarter worth about $171,000. Finally, Intech Investment Management LLC bought a new position in shares of CARGO Therapeutics in the fourth quarter worth about $181,000. 93.16% of the stock is currently owned by hedge funds and other institutional investors.

CARGO Therapeutics Stock Performance

Shares of CARGO Therapeutics stock traded up $0.06 during trading on Wednesday, reaching $4.56. The company's stock had a trading volume of 514,100 shares, compared to its average volume of 552,889. The business's fifty day moving average price is $4.23 and its 200-day moving average price is $8.03. The firm has a market cap of $210.26 million, a price-to-earnings ratio of -1.07 and a beta of 0.47. CARGO Therapeutics, Inc. has a one year low of $3.00 and a one year high of $25.45.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.